STC-15

STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases[1][2][3].

Product Specifications

CAS Number

[2648257-56-9]

UNSPSC

12352005

Target

METTL3

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/stc-15.html

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C=C(C(NCC2=CC3=C(C=C(CNCC4CCC4)N3)C=C2)=O)N=C5C=CC=CN15

Molecular Formula

C24H25N5O2

Molecular Weight

415.49

References & Citations

[1]Wesley Peter Blackaby, et al. Polyheterocyclic compounds as mettl3 inhibitors. Patent WO2021111124A1. |[2]Ofir-Rosenfeld Y, et al. STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade[J]. European Journal of Cancer, 2022, 174: S123.|[3]Ofir-Rosenfeld Y, et al. STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[C]//MOLECULAR CANCER THERAPEUTICS. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2023, 22 (12) .